Voter support for psychedelic research, therapy and prescription access all surged. Decrim didn’t move. A new Berkeley survey says it out loud. The Short Version Voter support for psychedelic research jumped 14 points to 63% in two years. Support for prescription-medicine access climbed 12. Therapeutic-use legalization rose 10. Decriminalization moved a statistically insignificant one point.… Keep Reading
President Trump signed an executive order on April 18 directing the FDA to fast-track review of psychedelic therapies and committing $50 million to ibogaine research. The psychedelics community is cautiously optimistic, and watching closely. President Donald Trump signed an executive order on Saturday directing federal agencies to accelerate research into psychedelic therapies and allocating $50… Keep Reading
Psychedelic legislation is moving through more state capitols simultaneously than at any point in history. The question is not whether reform is coming. It is whether it will be done right. In March 2026, Oregon signed into law significant modifications to its psilocybin services program, the first regulated psychedelic access system in the country, now… Keep Reading
